A computationally designed IL-2; plus Adimab/Mapp, Kahr and more

Stanford University scientists, including  Synthekine Inc. founder K. Christopher Garcia, used computational design to make affinity-enhanced, thermostable IL-2 variants with up to 40-fold higher affinity for IL2RB. The strategy, published in PNAS, focused on stabilizing core protein structures rather than engineering the protein–protein interface.

There is a well-stocked pipeline of engineered IL-2 variants, fusions and antibody conjugates aimed at reducing binding to IL2RA to activate cancer-killing effector T cells while avoiding activation of immunosuppresive regulatory T cells...